Benchmark started coverage on shares of Acasti Pharma (NASDAQ:ACST) in a research note published on Friday, January 5th. The firm issued a buy rating and a $7.00 target price on the biopharmaceutical company’s stock.
Separately, ValuEngine upgraded shares of Acasti Pharma from a sell rating to a hold rating in a research report on Monday, November 20th.
Acasti Pharma (NASDAQ ACST) remained flat at $$0.96 during mid-day trading on Friday. 214,092 shares of the company traded hands, compared to its average volume of 629,908. Acasti Pharma has a 52 week low of $0.84 and a 52 week high of $3.36. The company has a market capitalization of $14.32, a price-to-earnings ratio of -1.31 and a beta of 1.42.
TRADEMARK VIOLATION WARNING: “Acasti Pharma (ACST) Coverage Initiated by Analysts at Benchmark” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/13/acasti-pharma-acst-receives-new-coverage-from-analysts-at-benchmark.html.
Acasti Pharma Company Profile
Acasti Pharma Inc is a Canada-based biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids (OM3s) derived from krill oil. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia (HTG).
Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.